非囊腫纖維化支氣管擴張市場：全球藥物類別與地區分析與預測（2025-2035）

Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年05月21日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

非囊腫纖維化支氣管擴張症 (NCFB) 的診斷是透過高解析度電腦斷層掃描和肺功能測試進行的，治療通常包括使用抗生素控制感染疾病、使用黏液溶解劑清除黏液、使用支氣管擴張劑改善氣流以及進行肺部復健。

透過適當的管理，包括預防感染和控制症狀，患者可以改善生活品質，但這種疾病會隨著時間的推移逐漸降低肺功能。

非囊腫纖維化支氣管擴張症市場的主要驅動力之一是人們對該疾病的認知不斷提高以及診斷水平不斷提高。隨著醫療保健專業人員對該疾病及其症狀的了解不斷加深，越來越多的患者在早期得到診斷。這一趨勢得到了診斷技術的進步的支持，例如高解析度電腦斷層掃描，它可以準確檢測出支氣管擴張的特徵性氣道擴張。隨著人們認知的提高和診斷技術的改進，非囊腫纖維化支氣管擴張已被認可為一種單獨的疾病實體，從而可以更早地進行治療並改善症狀管理。這反過來又推動了對抗生素、祛痰藥、支氣管擴張劑和生物製藥等有效治療方法的需求，從而推動了市場成長。

然而，儘管市場不斷成長，但仍存在一些挑戰阻礙著進步並限制了治療的效果。主要挑戰之一是缺乏美國FDA核准的針對非囊腫纖維化支氣管擴張的特定治療方法。目前使用的許多治療方法都是對核准治療其他疾病（如囊腫纖維化和慢性阻塞性肺病(COPD)）的藥物的仿單標示外的使用，因此很難制定標準的治療指南。此外，生物製藥、長期抗生素治療和吸入療法等先進治療方法高成本，限制了人們獲得治療的機會，特別是對於低收入社區和保險不足的患者而言。

此外，由於疾病的多樣性，很難制定出一種通用於所有患者的統一治療方法。這是因為非囊腫纖維化支氣管擴張在每位患者身上的表現不同，病因、嚴重程度和治療反應也不同。此外，延遲診斷往往會導致嚴重疾病，使治療複雜化，並限制現有治療方法的有效性。此外，醫護人員和公眾缺乏意識，導致診斷延遲或被忽視，這在醫療資源有限的地區尤其嚴重。這些挑戰強調了加速有針對性的研究、核准特定治療方法以及改善醫療服務的必要性。

本報告調查了全球非囊腫纖維化支氣管擴張市場，並總結了主要趨勢、市場影響因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

Non-Cystic fibrosis bronchiectasis (NCFB) is a chronic lung condition characterized by the permanent widening and scarring of the bronchi, the airways in the lungs. Unlike as cystic fibrosis, Non-cystic fibrosis bronchiectasis occurs in individuals without the genetic disorder and is typically caused by recurrent respiratory infections, autoimmune diseases, immunodeficiency disorders, or aspiration of food and liquids into the lungs. The condition leads to the accumulation of mucus in the airways, which makes it difficult for the body to clear bacteria and other pathogens, resulting in frequent infections, chronic cough, sputum production, and shortness of breath. While the exact cause can vary, many cases of non-cystic fibrosis bronchiectasis are associated with chronic inflammation and repeated bacterial infections. Diagnosis is made through high-resolution CT scans and lung function tests, and treatment typically involves antibiotics to manage infections, mucolytics to clear mucus, bronchodilators to improve airflow, and pulmonary rehabilitation. With proper management, including infection prevention and symptom control, patients can improve their quality of life, although the disease may progressively impair lung function over time.

One of the key drivers of the non-cystic fibrosis bronchiectasis market is the increasing awareness and improved diagnosis of the condition. As healthcare professionals gain a better understanding of non-cystic fibrosis bronchiectasis and its symptoms, more patients are being diagnosed at earlier stages.

This has been facilitated by advancements in diagnostic technologies such as high-resolution CT scans, which are able to detect airway dilation characteristic of bronchiectasis more accurately. With greater awareness and better diagnostic capabilities, there is a growing recognition of non-cystic fibrosis bronchiectasis as a distinct disease, leading to earlier treatment and better management of symptoms. As a result, the demand for effective therapies, including antibiotics, mucolytics, bronchodilators, and biologic treatments, is on the rise, driving market growth.

Despite the growth of the non-cystic fibrosis bronchiectasis market, several challenges continue to hinder its progress and the overall effectiveness of treatment. One major issue is the lack of specific FDA-approved therapies for non-cystic fibrosis bronchiectasis, with most treatments being off-label uses of drugs approved for other conditions such as cystic fibrosis or chronic obstructive pulmonary disease (COPD). This limits treatment options and makes it harder to develop standardized treatment protocols. Another challenge is the high cost of advanced therapies, such as biologics, long-term antibiotics, and inhalation treatments, which can be prohibitively expensive, limiting access for patients, especially in low-income regions or for those without comprehensive insurance coverage.

Additionally, disease heterogeneity makes it difficult to develop one-size-fits-all therapies, as Non-cystic fibrosis bronchiectasis presents differently in various patients, with different underlying causes, severity, and response to treatment. Moreover, late-stage diagnosis often results in more severe disease, which complicates treatment and limits the effectiveness of available therapies. There is also a lack of awareness among healthcare providers and the general public, leading to delays in diagnosis and underdiagnosis, particularly in regions with limited access to healthcare resources. These challenges emphasize the need for targeted research, regulatory approval of specific therapies, and improved healthcare access to better manage non-cystic fibrosis bronchiectasis.

The global non-cystic fibrosis bronchiectasis market is highly competitive, with several leading pharmaceutical companies playing a pivotal role in advancing treatments for this chronic respiratory disease. Major players such as AstraZeneca, GlaxoSmithKline (GSK), Novartis, Boehringer Ingelheim, Pfizer, Vertex Pharmaceuticals, Genentech (Roche), Chiesi Pharmaceuticals, and Teva Pharmaceutical Industries are actively developing a range of therapies, including bronchodilators, mucolytics, antibiotics, and biologic treatments. These companies are focused on improving patient outcomes by targeting the underlying causes of non-cystic fibrosis bronchiectasis, such as chronic inflammation and recurrent infections, while also enhancing symptom management. As research in personalized medicine and novel therapies continues to evolve, these companies are positioned to significantly impact the Non-Cystic fibrosis bronchiectasis market, offering better options for those suffering from non-cystic fibrosis bronchiectasis and aiming to improve their quality of life.

Market Segmentation:

Segmentation 1: by Drug Class

Antibiotics
Corticosteroids
Bronchodilators
Others

Segmentation 2: by Region

North America
Europe
Asia-Pacific

The global non-cystic fibrosis bronchiectasis market is experiencing several key emerging trends that are significantly shaping the future of treatment. One of the most prominent trends is the shift towards personalized medicine, where treatments are becoming more tailored to individual patients based on their specific genetic, microbial, and disease characteristics. This approach aims to improve the effectiveness of therapies while minimizing side effects.

Additionally, there is a growing emphasis on the development of novel biologic therapies and targeted treatments that address the underlying inflammation and infection that drive the progression of non-cystic fibrosis bronchiectasis. The use of advanced diagnostics, such as high-resolution CT scans and microbial profiling, is enabling earlier and more accurate diagnosis, leading to more precise and timely interventions. Another significant trend is the increased focus on combination therapies, where medications such as bronchodilators, antibiotics, and mucolytics are used together to target multiple aspects of the disease. These trends are driving innovation in the market, offering hope for better management and improved quality of life for patients with non-cystic fibrosis bronchiectasis.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Non-Cystic Fibrosis Bronchiectasis Market: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology Analysis
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Non-Cystic Fibrosis Bronchiectasis Market, by Drug Class, $Million, 2023-2035

2.1 Antibiotics
2.2 Corticosteroids
2.3 Bronchodilators,
2.4 Others

3. Global Non-Cystic Fibrosis Bronchiectasis Market (Region), ($Million), 2023-2035

3.1 North America
- 3.1.1 Key Findings
- 3.1.2 Market Dynamics
- 3.1.3 Market Sizing and Forecast
  - 3.1.3.1 North America Non-Cystic Fibrosis Bronchiectasis Market, by Country
    - 3.1.3.1.1 U.S.
3.2 Europe
- 3.2.1 Key Findings
- 3.2.2 Market Dynamics
- 3.2.3 Market Sizing and Forecast
  - 3.2.3.1 Europe Non-Cystic Fibrosis Bronchiectasis Market, by Country
    - 3.2.3.1.1 Germany
    - 3.2.3.1.2 U.K.
    - 3.2.3.1.3 France
    - 3.2.3.1.4 Italy
3.3 Asia Pacific
- 3.3.1 Key Findings
- 3.3.2 Market Dynamics
- 3.3.3 Market Sizing and Forecast
  - 3.3.3.1 Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market, by Country
    - 3.3.3.1.1 Japan

4. Global Non-Cystic Fibrosis Bronchiectasis Market: Competitive Landscape and Company Profiles

4.1 Key Strategies and Development
- 4.1.1 Mergers and Acquisitions
- 4.1.2 Synergistic Activities
- 4.1.3 Business Expansions and Funding
- 4.1.4 Product Launches and Approvals
- 4.1.5 Other Activities
4.2 Company Profiles
- 4.2.1 AstraZeneca
  - 4.2.1.1 Overview
  - 4.2.1.2 Top Products / Product Portfolio
  - 4.2.1.3 Top Competitors
  - 4.2.1.4 Target Customers/End-Users
  - 4.2.1.5 Key Personnel
  - 4.2.1.6 Analyst View
- 4.2.2 Sanofi
  - 4.2.2.1 Overview
  - 4.2.2.2 Top Products / Product Portfolio
  - 4.2.2.3 Top Competitors
  - 4.2.2.4 Target Customers/End-Users
  - 4.2.2.5 Key Personnel
  - 4.2.2.6 Analyst View
- 4.2.3 Insmed
  - 4.2.3.1 Overview
  - 4.2.3.2 Top Products / Product Portfolio
  - 4.2.3.3 Top Competitors
  - 4.2.3.4 Target Customers/End-Users
  - 4.2.3.5 Key Personnel
  - 4.2.3.6 Analyst View
- 4.2.4 Boehringer Ingelheim
  - 4.2.4.1 Overview
  - 4.2.4.2 Top Products / Product Portfolio
  - 4.2.4.3 Top Competitors
  - 4.2.4.4 Target Customers/End-Users
  - 4.2.4.5 Key Personnel
  - 4.2.4.6 Analyst View
- 4.2.5 Zambon
  - 4.2.5.1 Overview
  - 4.2.5.2 Top Products / Product Portfolio
  - 4.2.5.3 Top Competitors
  - 4.2.5.4 Target Customers/End-Users
  - 4.2.5.5 Key Personnel
  - 4.2.5.6 Analyst View
- 4.2.6 Chiesi Pharmaceuticals
  - 4.2.6.1 Overview
  - 4.2.6.2 Top Products / Product Portfolio
  - 4.2.6.3 Top Competitors
  - 4.2.6.4 Target Customers/End-Users
  - 4.2.6.5 Key Personnel
  - 4.2.6.6 Analyst View
- 4.2.7 Haisco Pharmaceutical Group
  - 4.2.7.1 Overview
  - 4.2.7.2 Top Products / Product Portfolio
  - 4.2.7.3 Top Competitors
  - 4.2.7.4 Target Customers/End-Users
  - 4.2.7.5 Key Personnel
  - 4.2.7.6 Analyst View
- 4.2.8 Regeneron Pharmaceuticals
  - 4.2.8.1 Overview
  - 4.2.8.2 Top Products / Product Portfolio
  - 4.2.8.3 Top Competitors
  - 4.2.8.4 Target Customers/End-Users
  - 4.2.8.5 Key Personnel
  - 4.2.8.6 Analyst View

5. Research Methodology

簡介目錄圖表

List of Figures

Figure: Global Non-Cystic Fibrosis Bronchiectasis Market (by Region), $Million, 2024 and 2035
Figure: Global Non-Cystic Fibrosis Bronchiectasis Market Key Trends, Analysis

List of Tables

Table: Global Non-Cystic Fibrosis Bronchiectasis Market Dynamics, Impact Analysis
Table: Global Non-Cystic Fibrosis Bronchiectasis Market (by Drug Class), $Million, 2023-2035
Table: Global Non-Cystic Fibrosis Bronchiectasis Market (by Region), $Million, 2023-2035

02-2729-4219

+886-2-2729-4219